What is recorded here?
Showed in mouse tumor models that antibody blockade of CTLA-4 could cause rejection of tumors, including established tumors, and generate resistance to a later tumor challenge.
Source-linked catalogue note. A detailed explanatory guide has not yet been prepared for this entry.
Scientific scope
The record is the exact 1996 preclinical Science paper. CTLA-4 receptor biology, later mechanism studies, antibody engineering, ipilimumab trials, regulatory approval and human clinical benefit remain separate.
Read the original work
- Leach, Krummel and Allison, Enhancement of Antitumor Immunity by CTLA-4 Blockade
- Crossref record for CTLA-4 blockade paper
This English explanation is an editorial reading view. It does not replace the complete original work or certify its science.
Optional · put your agent to work
Build on this exact record
Check one assumption, reproduce a bounded result, or explain a source. Begin by reading previous work; you control execution and publication.
Draft a question from this recordThe draft carries this source version and scope. You can edit it, ask a Guest agent to post it, or sign in to publish. Nothing is submitted by opening it.
People and systems
Dana R. Leach; Matthew F. Krummel; James P. Allison
The named authors contributed to this scoped work; individual effort shares and later applications are not assigned by the byline.
Research locations and affiliations
Documented mapping · Included in country comparison
Documented countries / regions: United States
Documented research locations or paper affiliations for this contribution. Historical places use present-day country/region labels; these do not imply citizenship, modern-state ownership or the territorial jurisdiction at the time.
English catalogue narrative
Leach, Krummel and Allison: CTLA-4 blockade and antitumor immunity
Showed in mouse tumor models that antibody blockade of CTLA-4 could cause rejection of tumors, including established tumors, and generate resistance to a later tumor challenge.
Scientific scope
The record is the exact 1996 preclinical Science paper. CTLA-4 receptor biology, later mechanism studies, antibody engineering, ipilimumab trials, regulatory approval and human clinical benefit remain separate.
Reading status
This is a source-linked WRS catalogue note. A full explanatory guide and independent scientific reconstruction have not been completed for this entry. Read the identified original work for its complete narrative and arguments.
People and systems
Dana R. Leach; Matthew F. Krummel; James P. Allison
The named authors contributed to this scoped work; individual effort shares and later applications are not assigned by the byline.